We are a Med-Tech company that impacts Patients, Payers and Providers along with adjacent industries such as pharma. We are introducing MiCure - a Remote Patient Monitoring product (SaaS) with chat assistant "Alice"(device) for end-to-end post-surgery care.
Product key focus area are reducing preventable-
- 30-days hospital readmission ~ around 4 million population gets readmission every year.
- Emergency revisits (treat and release) ~ around 0.1 billion population gets into emergency .
- End-to-end support for patient regimen adherence (limited programs offers).
- Improving an average stay post surgery in hospital and many more.
To know more, refer our PUBLIC DECK -> here
Background-
- American Hospital Association(AHA) report states that hospital labor expenses rose to their highest of $86 billion in 2022 and hospital expenses overall increased by nearly $135 billion in 2022 over 2021.
- Inflation is a huge concern for US payers as more than 1,200 drug products saw price hikes that outpaced inflation between July 2021 and July 2022, with an average increase of 31.6%, according to the Department of Health and Human Services (HHS).
- The healthcare industry is moving beyond conventional care and is primed for enablement through RPM.
- The RPM market in home healthcare alone is expected to grow at CAGR 20.08% reaching $16.9 billion by 2030.
- Despite this , RPM suites currently offered in the market are unable to cater the end-to-end requirements of home hospitalization.
- MiCure is an end-to-end solution for Patients, Payers and Providers keeping track of the entire post surgical care regimen (HITRUST Complaint).
Product Status–
- Minimum Viable Product (MVP) achieved.
- Testing for the first patient under postpartum care on 'pain management'.
- Reaching out large systems for product briefing and feedbacks.
- Unique algorithms are under USPTO provisional.
Ask-
We look for investment groups which focus on medical devices and tech
. Our ask is for piloting FDA complaint product under large hospital systems and submitting the piloting data for FDA Clearance. As a healthcare investor if you/your organization is interested in knowing MiCure more, we would love to have a conversation with you (
calendar link). Do let us know if you have questions in mind or suggestions.
Important: FDA is moving to use the e-STAR 510k submission pathway on Oct 1, 2023. It will cut down on back-and-forth questions regarding the administrative review hence reducing the timelines.
“I believe this product cannot just reduce revisits of patients, but also engage them in a regimen. I recommend including multiple languages and gesture-based communications..” - Senior RN, Mount Sinai
Suruchi Sinha (She/Her) | LinkedInFounder | CEO
Tushar Srivastava(He/Him)|LinkedIn
Co-founder| CSO
Ready to Ask For Funding for your company?
Post a Funding Request